SUVEN Life Sciences

Communication to investors

Dec 2012

Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

FINANCIAL QUICK VIEW
Quarter 3 – Dec 2012

- Growth in revenue   25.03%
- Growth in PAT   499.21%
- Growth in EBIDTA   613.01%
- Growth in Pre-R&D EBIDTA   128.91%
- Increase in R&D costs   8.36%
- R&D cost on revenue   14.81%

FINANCIAL QUICK VIEW
9 months – Dec 2012

- Growth in revenue   26.94%
- Growth in PAT   207.75%
- Growth in EBIDTA   248.11%
- Growth in Pre-R&D EBIDTA   78.73%
- Increase in R&D costs   0.16%
- R&D cost on revenue   13.54%

MAJOR PROFITABILITY RATIOS

	Q3 Dec 12	Upto Dec 12
PAT to Income	12.36%	12.09%
EBIDTA to Income	24.27%	21.83%
Cash Flow to Income	15.85%	15.21%
Pre-R&D EBITDA to Income	39.09%	35.37%

INCOME COMPARISON

2012-13 Q3 results

PROFIT COMPARISON

12-Feb-13

2012-13 Q3 results

EBIDTA COMPARISON

2012-13 Q3 results

12-Feb-13

R & D – EXPENDITURE

12-Feb-13

2012-13 Q3 results

PRE-R&D EBIDTA

2012-13 Q3 results

PRE-R&D CASHFLOW

Chart: Rupees Million

- Qtr Dec11: 112.57
- Qtr Dec12: 192.44
- PE Dec11: 362.18
- PE Dec12: 528.04

Updates for the quarter

During the quarter there were major qualitative achievements with the grant of 8 (eight) product patents to Suven's drug discovery pipeline from Canada, China, Eurasia and Korea which consists of 13 molecules out of which twelve (12) molecules currently in pre-clinical stage of development in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.